Cargando…

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality rate. Although the current standard therapy consists of surgery followed by radiation and temozolomide (TMZ), chemotherapy can extend patient’s post-operative survival but most cases eventually demonstrate res...

Descripción completa

Detalles Bibliográficos
Autores principales:	JIAPAER, Shabierjiang, FURUTA, Takuya, TANAKA, Shingo, KITABAYASHI, Tomohiro, NAKADA, Mitsutoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japan Neurosurgical Society 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186761/ https://www.ncbi.nlm.nih.gov/pubmed/30249919 http://dx.doi.org/10.2176/nmc.ra.2018-0141

Ejemplares similares

Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma
por: Kitabayashi, Tomohiro, et al.
Publicado: (2019)

RBPJ contributes to the malignancy of glioblastoma and induction of proneural‐mesenchymal transition via IL‐6‐STAT3 pathway
por: Zhang, Guangtao, et al.
Publicado: (2020)

Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
por: Dong, Yu, et al.
Publicado: (2017)

Gelsolin inhibits malignant phenotype of glioblastoma and is regulated by miR‐654‐5p and miR‐450b‐5p
por: Zhang, Jiakang, et al.
Publicado: (2020)

The strategy for enhancing temozolomide against malignant glioma
por: Nakada, Mitsutoshi, et al.
Publicado: (2012)

Therapeutic potential of pentamidine for glioma‐initiating cells and glioma cells through multimodal antitumor effects
por: Tamai, Sho, et al.
Publicado: (2023)

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
por: Wang, Chun, et al.
Publicado: (2023)

CBMS-12 PENTAMIDINE; TRANSLATIONAL RESEARCH FOR A NEW CHEMOTHERAPY TARGETING ON GLIOMA CELLS AND GLIOMA STEM CELLS USING DRUG REPOSITIONING
por: Tamai, Sho, et al.
Publicado: (2019)

Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells
por: Zhao, Kai, et al.
Publicado: (2021)

ES-2 Phase 3 TRIDENT Trial: Radiation and Temozolomide with or without Tumor Treating Fields in newly diagnosed glioblastoma
por: Nakada, Mitsutoshi
Publicado: (2020)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines
por: Malacrida, Alessio, et al.
Publicado: (2022)

Nucleoporin TPR (translocated promoter region, nuclear basket protein) upregulation alters MTOR-HSF1 trails and suppresses autophagy induction in ependymoma
por: Dewi, Firli Rahmah Primula, et al.
Publicado: (2020)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

In search of effective therapies to overcome resistance to Temozolomide in brain tumours
por: Bouzinab, Kaouthar, et al.
Publicado: (2019)

Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
por: Zhou, Weihua, et al.
Publicado: (2019)

Mifepristone Overcomes Tumor Resistance to Temozolomide Associated with DNA Damage Repair and Apoptosis in an Orthotopic Model of Glioblastoma
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2018)

Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD(+) Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase
por: Li, Jianfeng, et al.
Publicado: (2022)

A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines
por: Brandt, Barbara, et al.
Publicado: (2023)

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
por: Singh, Neha, et al.
Publicado: (2021)

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
por: Almeida Lima, Karoline, et al.
Publicado: (2023)

MPC-06 LRG1 HAS MULTIPLE POTENTIAL FOR CLINICOPATHOLOGICAL BIOMARKER OF GLIOBLASTOMA
por: Furuta, Takuya, et al.
Publicado: (2019)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
por: Ohba, Shigeo, et al.
Publicado: (2021)

IM-01 PI3K GAMMA INHIBITOR FOR OVERCOMING TREATMENT RESISTANCE IN COMBINATION THERAPY OF TEMOZOLOMIDE AND ANTI-PDL1 ANTIBODY FOR GLIOBLASTOMA PATIENTS
por: Ishikawa, Eiichi, et al.
Publicado: (2019)

Overcoming TRAIL Resistance for Glioblastoma Treatment
por: Deng, Longfei, et al.
Publicado: (2021)

Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment
por: Miyazaki, Tsubasa, et al.
Publicado: (2020)

Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy
por: Urbantat, Ruth M., et al.
Publicado: (2021)

Cerebral Infarction Related to Carmustine Wafers in Glioblastoma: A Case Report
por: Nakada, Mitsutoshi, et al.
Publicado: (2014)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Critical Neural Networks in Awake Surgery for Gliomas
por: KINOSHITA, Masashi, et al.
Publicado: (2016)

Relation between autophagy and the resistence of glioblastoma cells to temozolomide
por: Carmo, Anália, et al.
Publicado: (2010)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

Metformin treatment reduces temozolomide resistance of glioblastoma cells
por: Yang, Seung Ho, et al.
Publicado: (2016)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
por: Fu, Xiaoyu, et al.
Publicado: (2023)

Glycogen synthase kinase‐3β is a pivotal mediator of cancer invasion and resistance to therapy
por: Domoto, Takahiro, et al.
Publicado: (2016)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
por: Tsai, Yu-Ling, et al.
Publicado: (2020)

Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres
por: Kim, Hee Yeon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8cpmcnlkauvj70d80tmkqbilhp